Electro Core, Inc. ECOR
We take great care to ensure that the data presented and summarized in this overview for electroCore, Inc. is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Latest Institutional Activity in ECOR
Top Purchases
Top Sells
About ECOR
electroCore, Inc., a commercial stage medical device company, engages in the development and commercialization of a range of non-invasive vagus nerve stimulation (nVNS) therapies. The company is developing gammaCore, a prescription-only nVNS therapy for the acute treatment of pain associated with migraine and episodic cluster headache in adults. Its lead product is gammaCore Sapphire, a rechargeable and reloadable handheld device for regular or intermittent use over many years. The company was incorporated in 2005 and is headquartered in Rockaway, New Jersey.
Insider Transactions at ECOR
Insider Transaction List
View all| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Sep 03
2024
|
Thomas M Patton Director |
BUY
Grant, award, or other acquisition
|
Direct |
16,583
+16.52%
|
-
|
|
Sep 03
2024
|
John P Gandolfo Director |
BUY
Grant, award, or other acquisition
|
Direct |
16,583
+19.77%
|
-
|
|
Sep 03
2024
|
Patricia Wilber Director |
BUY
Grant, award, or other acquisition
|
Direct |
16,583
+25.02%
|
-
|
|
Sep 03
2024
|
Thomas J. Errico Director |
BUY
Grant, award, or other acquisition
|
Direct |
16,583
+6.21%
|
-
|
|
Sep 03
2024
|
Charles Steve Theofilos |
BUY
Grant, award, or other acquisition
|
Direct |
16,582
+3.52%
|
-
|
|
Aug 15
2024
|
Thomas J. Errico Director |
BUY
Open market or private purchase
|
Direct |
5,000
+2.09%
|
$30,000
$6.12 P/Share
|
|
Jun 13
2024
|
John P Gandolfo Director |
BUY
Open market or private purchase
|
Direct |
1,000
+1.93%
|
$6,000
$6.43 P/Share
|
|
Jun 05
2024
|
Thomas J. Errico Director |
BUY
Grant, award, or other acquisition
|
Direct |
38,505
+14.4%
|
$231,030
$6.43 P/Share
|
|
Jun 05
2024
|
Daniel S Goldberger Chief Executive Officer |
BUY
Open market or private purchase
|
Direct |
38,505
+13.37%
|
$231,030
$6.43 P/Share
|
|
Jun 05
2024
|
Thomas M Patton Director |
BUY
Grant, award, or other acquisition
|
Direct |
7,701
+10.28%
|
$46,206
$6.43 P/Share
|
|
Jun 05
2024
|
Julie Ann Goldstein Director |
BUY
Grant, award, or other acquisition
|
Direct |
7,701
+9.05%
|
$46,206
$6.43 P/Share
|
|
Jun 05
2024
|
Patricia Wilber Director |
BUY
Grant, award, or other acquisition
|
Direct |
6,931
+17.31%
|
$41,586
$6.43 P/Share
|
|
Jan 16
2024
|
Daniel S Goldberger Chief Executive Officer |
BUY
Grant, award, or other acquisition
|
Direct |
75,000
+26.22%
|
-
|
|
Jan 12
2024
|
Brian M Posner Chief Financial Officer |
BUY
Open market or private purchase
|
Direct |
16,000
+41.63%
|
-
|
|
Jan 01
2024
|
Charles Steve Theofilos |
BUY
Grant, award, or other acquisition
|
Direct |
25,210
+5.45%
|
-
|
|
Sep 15
2023
|
Daniel S Goldberger Chief Executive Officer |
BUY
Open market or private purchase
|
Direct |
1,500
+1.09%
|
$7,500
$5.55 P/Share
|
|
Aug 04
2023
|
Thomas J. Errico Director |
BUY
Grant, award, or other acquisition
|
Direct |
21,739
+10.29%
|
-
|
|
Aug 04
2023
|
Thomas M Patton Director |
BUY
Grant, award, or other acquisition
|
Direct |
21,739
+26.76%
|
-
|
|
Aug 04
2023
|
Daniel S Goldberger Chief Executive Officer |
BUY
Open market or private purchase
|
Direct |
50,000
+27.09%
|
-
|
|
Aug 04
2023
|
John P Gandolfo Director |
BUY
Grant, award, or other acquisition
|
Direct |
21,739
+30.43%
|
-
|
Last 12 Months Summary
| Grant, award, or other acquisition | 244K shares |
|---|---|
| Open market or private purchase | 60.5K shares |